Empowered Funds LLC Makes New Investment in Boston Scientific Corporation $BSX

Empowered Funds LLC acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 114,625 shares of the medical equipment provider’s stock, valued at approximately $4,892,000.

Other hedge funds also recently made changes to their positions in the company. FWL Investment Management LLC purchased a new stake in Boston Scientific during the second quarter valued at about $26,000. Swiss RE Ltd. purchased a new position in shares of Boston Scientific in the 4th quarter worth about $26,000. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific during the 4th quarter valued at about $26,000. Sfam LLC bought a new stake in Boston Scientific in the 4th quarter worth approximately $29,000. Finally, Cresta Advisors Ltd. bought a new stake in Boston Scientific in the 4th quarter worth approximately $33,000. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney acquired 186,240 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. The trade was a 13.27% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David C. Habiger purchased 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders purchased 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Robert W. Baird set a $56.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. The Goldman Sachs Group set a $71.00 target price on shares of Boston Scientific in a research report on Thursday, May 28th. Argus reissued a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Canaccord Genuity Group lowered their price target on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Finally, Wells Fargo & Company cut their price target on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research report on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Stock Performance

NYSE:BSX opened at $48.35 on Tuesday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The firm’s fifty day simple moving average is $46.65 and its 200 day simple moving average is $56.35. The stock has a market cap of $70.07 billion, a P/E ratio of 19.57, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has initiated a stock repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.